Madrigal Pharmaceuticals completes $500M stock sale as it prepares for potential launch of NASH treatment


A decision from the FDA on Madrigal's new drug application for its experimental NASH therapy is expected in the spring.

Previous Envoy Medical starts trading on NASDAQ as it tests cochlear implant
Next Metro Denver home sales drop but homebuyers aren’t seeing any relief